Table 3 Select novel targeted agents... | American Society of Hematology

Table 3

Select novel targeted agents under evaluation in DLBCL with postulated target and patient subgroup most likely to benefit

Agent	Target	Molecular subgroup
Bortezomib	NF-κB	ABC
Fostamatinib	SYK	ABC
Ibrutinib	BTK	ABC
Enzastaurin	PKCβ	ABC
Idelalisib	PI3K	(?) GCB
ABT-199	BCL2	(?) GCB, dual expressers
EZH2 inhibitors	EZH2	GCB
BCL6 inhibitors	BCL6	GCB
Lenalidomide	Microenvironment, NF-κB	ABC
Obinutuzumab	CD20	All
Ofatumomab	CD20	All
Polatuzumab vedotin	CD79b	All

Agent	Target	Molecular subgroup
Bortezomib	NF-κB	ABC
Fostamatinib	SYK	ABC
Ibrutinib	BTK	ABC
Enzastaurin	PKCβ	ABC
Idelalisib	PI3K	(?) GCB
ABT-199	BCL2	(?) GCB, dual expressers
EZH2 inhibitors	EZH2	GCB
BCL6 inhibitors	BCL6	GCB
Lenalidomide	Microenvironment, NF-κB	ABC
Obinutuzumab	CD20	All
Ofatumomab	CD20	All
Polatuzumab vedotin	CD79b	All